Choline PET/CT for imaging prostate canceran update

K. Kitajima; M. C. Robert; N. A. Mark; A. Kawashima

Choline PET/CT for imaging prostate canceran update

K. Kitajima, M. C. Robert, N. A. Mark, A. Kawashima

Diagnostic Radiology

Research output: Contribution to journal › Article › peer-review

Abstract

Whole-body integrated positron emission tomogra-phy/computed tomography (PET/CT) with [¹¹C] -and ¹⁸F -labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. ¹¹C- and ¹⁸F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, and this correct diagnosis impacts subsequent management, such as consideration of salvage therapy for local recurrence or systemic treatment for metastatic disease. ¹¹C- and ¹⁸F-choline PET/ CT have more limited roles for the initial staging of prostate cancer due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The present review discusses the current role of ¹¹C- and ¹⁸F-choline PET/CT in the management of prostate cancer, discussing its usefulness and limitations in the imaging of these patients.

Original language	English (US)
Pages (from-to)	279-288
Number of pages	10
Journal	Japanese Journal of Clinical Radiology
Volume	59
Issue number	2
State	Published - Feb 2014

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Cite this

@article{c2ca1366787f48bc941bf2b855c7c499,

title = "Choline PET/CT for imaging prostate canceran update",

abstract = "Whole-body integrated positron emission tomogra-phy/computed tomography (PET/CT) with [11C] -and 18F -labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. 11C- and 18F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, and this correct diagnosis impacts subsequent management, such as consideration of salvage therapy for local recurrence or systemic treatment for metastatic disease. 11C- and 18F-choline PET/ CT have more limited roles for the initial staging of prostate cancer due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The present review discusses the current role of 11C- and 18F-choline PET/CT in the management of prostate cancer, discussing its usefulness and limitations in the imaging of these patients.",

author = "K. Kitajima and Robert, {M. C.} and Mark, {N. A.} and A. Kawashima",

year = "2014",

month = feb,

language = "English (US)",

volume = "59",

pages = "279--288",

journal = "Japanese Journal of Clinical Radiology",

issn = "0009-9252",

publisher = "Kanehara Shuppan Co. Ltd",

number = "2",

}

TY - JOUR

T1 - Choline PET/CT for imaging prostate canceran update

AU - Kitajima, K.

AU - Robert, M. C.

AU - Mark, N. A.

AU - Kawashima, A.

PY - 2014/2

Y1 - 2014/2

N2 - Whole-body integrated positron emission tomogra-phy/computed tomography (PET/CT) with [11C] -and 18F -labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. 11C- and 18F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, and this correct diagnosis impacts subsequent management, such as consideration of salvage therapy for local recurrence or systemic treatment for metastatic disease. 11C- and 18F-choline PET/ CT have more limited roles for the initial staging of prostate cancer due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The present review discusses the current role of 11C- and 18F-choline PET/CT in the management of prostate cancer, discussing its usefulness and limitations in the imaging of these patients.

AB - Whole-body integrated positron emission tomogra-phy/computed tomography (PET/CT) with [11C] -and 18F -labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. 11C- and 18F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, and this correct diagnosis impacts subsequent management, such as consideration of salvage therapy for local recurrence or systemic treatment for metastatic disease. 11C- and 18F-choline PET/ CT have more limited roles for the initial staging of prostate cancer due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The present review discusses the current role of 11C- and 18F-choline PET/CT in the management of prostate cancer, discussing its usefulness and limitations in the imaging of these patients.

UR - http://www.scopus.com/inward/record.url?scp=84895797868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895797868&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84895797868

SN - 0009-9252

VL - 59

SP - 279

EP - 288

JO - Japanese Journal of Clinical Radiology

JF - Japanese Journal of Clinical Radiology

IS - 2

ER -

Choline PET/CT for imaging prostate canceran update

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this